What is included in ART prophylaxis for infants exposed to HIV?

1. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998 Oct 1. 12(14):1735-44. [Medline].

2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994 Nov 3. 331(18):1173-80. [Medline].

3. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999 Aug 5. 341 (6):394-402. [Medline].

4. Rahangdale L, Cohan D. Rapid human immunodeficiency virus testing on labor and delivery. Obstet Gynecol. 2008 Jul. 112(1):159-63. [Medline].

5. Centers for Disease Control and Prevention (CDC). Epidemiology of HIV/AIDS--United States, 1981-2005. MMWR Morb Mortal Wkly Rep. 2006 Jun 2. 55(21):589-92. [Medline].

6. Committee on Health Care for Underserved Women, The American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 536: Human immunodeficiency virus and acquired immunodeficiency syndrome and women of color. Obstet Gynecol. 2012 Sep. 120 (3):735-9. [Medline].

7. Joint United Nations Programme on HIV/AIDS (UNAIDS). Ending AIDS: Progress Towards the 90-90-90 Targets. Available at http://www.unaids.org/sites/default/files/media_asset/Global_AIDS_update_2017_en.pdf. 2017; Accessed: September 5, 2017.

8. Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000 Dec 22. 14(18):2913-20. [Medline].

9. Fowler MG, Qin M, Fiscus SA, et al. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. N Engl J Med. 2016 Nov 3. 375 (18):1726-1737. [Medline].

10. Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002 Jun 13. 346(24):1863-70. [Medline]. [Full Text].

11. Jao J, Agwu A, Mhango G, et al. Growth patterns in the first year of life differ in infants born to perinatally vs. nonperinatally HIV-infected women. AIDS. 2015 Jan 2. 29(1):111-6. [Medline].

12. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS. 2007 Mar 12. 21(5):607-15. [Medline].

13. Thorne C, Newell ML. The safety of antiretroviral drugs in pregnancy. Expert Opin Drug Saf. 2005 Mar. 4(2):323-35. [Medline].

14. Hitti J, Anderson J, McComsey G, et al. Effect of protease inhibitor-based antiretroviral therapy on glucose tolerance in pregnancy. Abstract. 13th Conference on Retroviruses and Opportunistic Infections. 2006 Feb.

15. Minkoff H, Hershow R, Watts DH, Frederick M, Cheng I, Tuomala R. The relationship of pregnancy to human immunodeficiency virus disease progression. Am J Obstet Gynecol. 2003 Aug. 189(2):552-9. [Medline].

16. Saada M, Le Chenadec J, Berrebi A, Bongain A, Delfraissy JF, Mayaux MJ. Pregnancy and progression to AIDS: results of the French prospective cohorts. SEROGEST and SEROCO Study Groups. AIDS. 2000 Oct 20. 14(15):2355-60. [Medline].

17. French R, Brocklehurst P. The effect of pregnancy on survival in women infected with HIV: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol. 1998 Aug. 105(8):827-35. [Medline].

18. [Guideline] Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1 Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. National Institutes of Health. Available at https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf. Accessed: September 5, 2017.

19. Centers for Disease Control and Prevention: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States. MMWR Morb Mortal Wkly Rep. September 2017. [Full Text].

20. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012 Aug 2. 367(5):399-410. [Medline].

21. Liao C, Wahab M, Anderson J, Coleman JS. Reclaiming fertility awareness methods to inform timed intercourse for HIV serodiscordant couples attempting to conceive. J Int AIDS Soc. 2015. 18(1):19447. [Medline].

22. Rough K, Tassiopoulos K, Kacanek D, et al. Dramatic decline in substance use by HIV-infected pregnant women in the United States from 1990 to 2012. AIDS. 2015 Jan 2. 29(1):117-23. [Medline]. [Full Text].

23. American College of Obstetrics and Gynecology. ACOG Committee Opinion No. 389, December 2007. Human immunodeficiency virus. Obstet Gynecol. 2007 Dec. 110(6):1473-8. [Medline].

24. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States: Special Populations: HIV/Hepatitis B Virus Coinfection. US Department of Health and Human Services. Available at https://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/159/hiv-hepatitis-b-virus-coinfection. October 26, 2016; Accessed: September 6, 2017.

25. Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol. 1998 Feb. 27(1):108-17. [Medline].

26. Mwapasa V, Rogerson SJ, Kwiek JJ, et al. Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi. AIDS. 2006 Sep 11. 20(14):1869-77. [Medline].

27. Massad LS, Xie X, Darragh T, et al. Genital Warts and Vulvar Intraepithelial Neoplasia: Natural History and Effects of Treatment and Human Immunodeficiency Virus Infection. Obstet Gynecol. 2011 Oct. 118(4):831-839. [Medline]. [Full Text].

28. Minkoff H. Human immunodeficiency virus infection in pregnancy. Obstet Gynecol. 2003 Apr. 101(4):797-810. [Medline].

29. Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010 Oct 14. 363(16):1499-509. [Medline].

30. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010 Oct 14. 363(16):1510-20. [Medline].

31. American College of Obstetrics and Gynecology. Scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. No. 234. Obstet Gynecol. 2000 (Reaffirmed 2015).

32. [Guideline] American College of Obstetrics and Gynecology. ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. Obstet Gynecol. 2007 Oct. 110(4):941-56. [Medline].

33. Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol. 2010 Jul. 116(1):147-59. [Medline].

34. Kind C, Rudin C, Siegrist CA, Wyler CA, Biedermann K, Lauper U. Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group. AIDS. 1998 Jan 22. 12(2):205-10. [Medline].

35. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA. 2001 Apr 25. 285(16):2083-93. [Medline].

36. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1--a meta-analysis of 15 prospective cohort studies. The International Perinatal HIV Group. N Engl J Med. 1999 Apr 1. 340(13):977-87. [Medline].

37. Louis J, Landon MB, Gersnoviez RJ, Leveno KJ, Spong CY, Rouse DJ. Perioperative morbidity and mortality among human immunodeficiency virus infected women undergoing cesarean delivery. Obstet Gynecol. 2007 Aug. 110(2 Pt 1):385-90. [Medline].

38. Wiysonge CS, Shey M, Kongnyuy EJ, Sterne JA, Brocklehurst P. Vitamin A supplementation for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2011 Jan 19. CD003648. [Medline].

39. Fowler MG, Lampe MA, Jamieson DJ, Kourtis AP, Rogers MF. Reducing the risk of mother-to-child human immunodeficiency virus transmission: past successes, current progress and challenges, and future directions. Am J Obstet Gynecol. 2007 Sep. 197(3 Suppl):S3-9. [Medline].

40. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2017. Wilmington, NC: Registry Coordinating Center; 2017; [Full Text].

41. Lighter-Fisher J, Surette AM. Performance of an interferon-gamma release assay to diagnose latent tuberculosis infection during pregnancy. Obstet Gynecol. 2012 Jun. 119 (6):1088-95. [Medline].

42. British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018. HIV Med. 2019 Mar. 20 Suppl 3:s2-s85. [Medline].

Ashley T Peterson, MD Fellow in Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Tufts Medical Center; Clinical Instructor, Department of Obstetrics and Gynecology, Tufts University School of Medicine

Ashley T Peterson, MD is a member of the following medical societies: American Congress of Obstetricians and Gynecologists, American Institute of Ultrasound in Medicine, Massachusetts Medical Society, Society for Maternal-Fetal Medicine

Disclosure: Nothing to disclose.

Linda C Kleeman, MD Assistant Professor, Department of Obstetrics and Gynecology, Tufts Medical Center; Course Director, Maternal-Fetal Medicine Acting Internship, Tufts University School of Medicine

Linda C Kleeman, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ronald M Ramus, MD Professor of Obstetrics and Gynecology, Director, Division of Maternal-Fetal Medicine, Virginia Commonwealth University School of Medicine

Ronald M Ramus, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Institute of Ultrasound in Medicine, Medical Society of Virginia, Society for Maternal-Fetal Medicine

Disclosure: Nothing to disclose.

Teresa Marino, MD Assistant Professor, Attending Physician, Division of Maternal-Fetal Medicine, Tufts Medical Center

Disclosure: Nothing to disclose.